Evidence map›Paper›PMID 40159497›Full record

ArticleNature communications2025

Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control.

Dimitri Belenki, Paulina Richter-Pechanska, Zhiting Shao, Animesh Bhattacharya, Andrea Lau, José Américo Nabuco Leva Ferreira de Freitas, Gregor Kandler, Timon P Hick, Xiurong Cai, Eva Scharnagl and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Dimitri BelenkiCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.ORCID http://orcid.org/0000-0002-9004-9849
Paulina Richter-PechanskaCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Zhiting ShaoCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Animesh BhattacharyaCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Andrea LauCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
José Américo Nabuco Leva Ferreira de FreitasIMRB, Mondor Institute for Biomedical Research, INSERM U955 - Université Paris Est Créteil, UPEC, Faculté de Médecine de Créteil, Créteil, France.ORCID http://orcid.org/0000-0003-3689-765X
Gregor KandlerCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Timon P HickCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Xiurong CaiCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Eva ScharnaglJohannes Kepler University, Medical Faculty, Linz, Austria.
Aitomi BittnerCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.ORCID http://orcid.org/0000-0001-6434-0950
Martin SchönleinCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Julia KaseCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Katharina PardonCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Bernadette BrzezichaExperimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, Germany.
Nina ThiessenCore Unit Bioinformatics - CUBI, Berlin Institute of Health, Berlin, Germany.
Oliver BischofIMRB, Mondor Institute for Biomedical Research, INSERM U955 - Université Paris Est Créteil, UPEC, Faculté de Médecine de Créteil, Créteil, France.ORCID http://orcid.org/0000-0003-2422-6277
Jan R DörrCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Maurice ReimannCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Maja MilanovicCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.ORCID http://orcid.org/0000-0003-1860-6003
Jing DuMedical Research Center and Department of Oncology Binzhou Medical University Hospital, 256600, Binzhou, P.R. China.
Yong YuJohannes Kepler University, Medical Faculty, Linz, Austria.ORCID http://orcid.org/0000-0003-1928-2514
Björn ChapuyCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Berlin, Germany.ORCID http://orcid.org/0000-0002-6485-8773
Soyoung LeeCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.ORCID http://orcid.org/0000-0002-4614-2931
Ulf LeserKnowledge Management in Bioinformatics, Institute for Computer Science, Humboldt-Universität zu Berlin, Berlin, Germany.
Claus ScheidereitMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0002-0446-6129
Jana WolfMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0003-3254-5868
Dorothy N Y FanCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany.
Clemens A SchmittCharité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Campus Virchow Klinikum, Berlin, Germany. clemens.schmitt@charite.de.ORCID http://orcid.org/0000-0002-4731-2226

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) e:Med program project SeneSys: 031L0189ABundesministerium für Gesundheit (Federal Ministry of Health, Germany) European Union ERA PerMed, HiRisk-HiGainDeutsche Forschungsgemeinschaft (German Research Foundation) GO 2688/1 1Deutsche Forschungsgemeinschaft (German Research Foundation) SCHM 1633/11-1Deutsche Forschungsgemeinschaft (German Research Foundation) SCHM 1633/9-2Deutsche Krebshilfe (German Cancer Aid) 7011377629
6 · The paper itself

Abstract

Cellular senescence is a stress-inducible state switch relevant in aging, tumorigenesis and cancer therapy. Beyond a lasting arrest, senescent cells are characterized by profound chromatin remodeling and transcriptional reprogramming. We show here myeloid-skewed aberrant lineage plasticity and its immunological ramifications in therapy-induced senescence (TIS) of primary human and murine B-cell lymphoma. We find myeloid transcription factor (TF) networks, specifically AP-1-, C/EBPβ- and PU.1-governed transcriptional programs, enriched in TIS but not in equally chemotherapy-exposed senescence-incapable cancer cells. Dependent on these master TF, TIS lymphoma cells adopt a lineage-promiscuous state with properties of monocytic-dendritic cell (DC) differentiation. TIS lymphoma cells are preferentially lysed by T-cells in vitro, and mice harboring DC-skewed Eμ-myc lymphoma experience significantly longer tumor-free survival. Consistently, superior long-term outcome is also achieved in diffuse large B-cell lymphoma patients with high expression of a TIS-related DC signature. In essence, these data demonstrate a therapeutically exploitable, prognostically favorable immunogenic role of senescence-dependent aberrant myeloid plasticity in B-cell lymphoma.

Indexed as

Cellular SenescenceLymphoma, B-CellT-LymphocytesAnimalsCell DifferentiationCell LineageCell Line, TumorCell PlasticityDendritic CellsFemaleGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMiceMice, Inbred C57BLProto-Oncogene ProteinsProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-Activators

Identifiers

PMID40159497
PMCPMC11955568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.